Lifeward reports record 2023 revenue $13.9M; Q4 rev $6.9M; FY2024 guidance $28-32M

Lifeward Ltd.

2023-FY EPS reported -$0.37 revenue$13,854,000

Record annual revenue $13.9M for FY2023, up 151% from $5.5M in FY2022.
Q4 2023 revenue $6.9M (+216% YoY); GAAP net loss $5.6M ($0.13/sh), adjusted net loss $3.3M ($0.05/sh).
Integration of ReWalk and AlterG complete; expected $3M in annual net savings in 2024.
CMS finalized Home Health Rule including exoskeletons in Medicare brace benefit effective Jan 1, 2024.
FY2024 revenue guidance $28-32M; non-GAAP gross margin high 40s%; Q1 2024 rev $5.0-5.5M (no Medicare revenue).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lifeward Ltd. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 27, 2024, ReWalk Robotics Ltd. (the "Company," "we" or "us") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

Lifeward Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-24-000726

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.